Your browser doesn't support javascript.
loading
Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study.
Zhang, Jin; Zhang, Wei; Yan, Jie; Ge, Qian; Lu, Xiao-Hong; Chen, Shao-Xing; Xu, Wen-Jie; Li, Ying; Li, Jin-Feng; He, Shi-Ying; Wang, Ji-Guang.
Afiliação
  • Zhang J; Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhang W; Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yan J; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.
  • Ge Q; Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Lu XH; Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Chen SX; Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Xu WJ; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.
  • Li Y; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.
  • Li JF; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.
  • He SY; Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, China.
  • Wang JG; Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. jiguangwang@rjh.com.cn.
Hypertens Res ; 46(8): 2024-2032, 2023 08.
Article em En | MEDLINE | ID: mdl-37258625
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipertensão Essencial / Anti-Hipertensivos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Humans / Middle aged Idioma: En Revista: Hypertens Res Assunto da revista: ANGIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipertensão Essencial / Anti-Hipertensivos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Humans / Middle aged Idioma: En Revista: Hypertens Res Assunto da revista: ANGIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido